No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BIIB Biogen
- 201.990
- +8.810+4.56%
Close Apr 24 16:00 ET
- 202.060
- +0.070+0.03%
Pre 05:45 ET
29.41BMarket Cap25.25P/E (TTM)
205.750High198.970Low3.27MVolume198.970Open193.180Pre Close660.09MTurnover2.26%Turnover Ratio25.34P/E (Static)145.60MShares319.76052wk High1.93P/B29.25BFloat Cap189.44052wk Low--Dividend TTM144.82MShs Float480.180Historical High--Div YieldTTM3.51%Amplitude2.625Historical Low202.129Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Biogen Non-GAAP EPS of $3.67 Beats by $0.21, Revenue of $2.29B Misses by $30M
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Biogen (BIIB) and Molina Healthcare (MOH)
Express News | Needham Reiterates Buy on Biogen, Maintains $294 Price Target
Biogen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 45.19% Needham → $294 Reiterates Buy → Buy 04/24/2024 45.19% Needham → $294 Reiterates Buy → Bu
Biogen Inc (BIIB) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic ...
Express News | Biogen Inc : Canaccord Genuity Raises Target Price to $308 From $305
Comments
Green day
Tesla, Visa and Boeing are popping in pre market after reporting their earnings.
Specifically for Tesla, it’s quite amazing that it is rallying off a very poor earnings.
Sometimes, the market rallies on bad earnings could be because the bad results weren’t as bad as previously feared. Sometimes, peope buy into the “future growth” theory.
Whether all these rebounds are dead cat bounces, it remains to be seen.
PS: definitely not complaining about this pop
$SPDR S&P 500 ETF(SPY.US$$S&P 500 Index(.SPX.US$$Visa(V.US$$Boeing(BA.US$$Texas Instruments(TXN.US$$Biogen(BIIB.US$$Airbnb(ABNB.US$$Bank of America(BAC.US$$Disney(DIS.US$$Apple(AAPL.US$$Meta Platforms(META.US$$Microsoft(MSFT.US$$NVIDIA(NVDA.US$$Taiwan Semiconductor(TSM.US$$Super Micro Computer(SMCI.US$$Coinbase(COIN.US$$Alphabet-A(GOOGL.US$
Specifically for Tesla, it’s quite amazing that it is rallying off a very poor earnings.
Sometimes, the market rallies on bad earnings could be because the bad results weren’t as bad as previously feared. Sometimes, peope buy into the “future growth” theory.
Whether all these rebounds are dead cat bounces, it remains to be seen.
PS: definitely not complaining about this pop
$SPDR S&P 500 ETF(SPY.US$$S&P 500 Index(.SPX.US$$Visa(V.US$$Boeing(BA.US$$Texas Instruments(TXN.US$$Biogen(BIIB.US$$Airbnb(ABNB.US$$Bank of America(BAC.US$$Disney(DIS.US$$Apple(AAPL.US$$Meta Platforms(META.US$$Microsoft(MSFT.US$$NVIDIA(NVDA.US$$Taiwan Semiconductor(TSM.US$$Super Micro Computer(SMCI.US$$Coinbase(COIN.US$$Alphabet-A(GOOGL.US$
From YouTube
3
5
ColumnsToday's Morning Movers and Top Ratings: TSLA, V, UBER, ABNB and More
Morning Movers
Gapping up
$Tesla(TSLA.US$ stock soared 12% following the announcement of earlier releases for "more affordable" car versions, despite first-quarter results falling short of Wall Street estimates.
$AT&T(T.US$ stock increased by 3.6% after reporting stronger-than-expected subscriber growth and surpassing free cash flow growth in the first quarter.
$Visa(V.US$ stock grew 2.4% as the credit card company's second...
Gapping up
$Tesla(TSLA.US$ stock soared 12% following the announcement of earlier releases for "more affordable" car versions, despite first-quarter results falling short of Wall Street estimates.
$AT&T(T.US$ stock increased by 3.6% after reporting stronger-than-expected subscriber growth and surpassing free cash flow growth in the first quarter.
$Visa(V.US$ stock grew 2.4% as the credit card company's second...
20
1
... 
ColumnsEli Lilly's Donanemab Nears Approval Decision, Could This Be a Turning Point in Alzheimer's Treatment?
The pharma giant $Eli Lilly and Co(LLY.US$ is on the cusp of a significant breakthrough with its Alzheimer's drug, donanemab. Following the completion of its Phase 3 trials, donanemab is currently undergoing FDA review and has the potential to receive approval later this month. If approved, it would be the second anti-Aβ therapy for Alzheimer's disease to receive full clearance from the U.S. FD...
70
Despite significant insider buying, Biogen's performance last year was worse than the annualised loss of 6% over the last half decade. Investors are advised to ensure they are buying a high quality business, as Biogen is showing 2 warning signs in investment analysis.
Wedbush Securities analyst Laura Chico suggests that Wall Street needs to reset its projections for Leqembi, and Biogen's turnaround story remains a work in progress. Biogen's CEO, Chris Viehbacher, sees Alzheimer's as the core franchise of Biogen going forward.
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Dramericanjesus : Tesla used a bullshit stock pump to keep it's stock price afloat after horrendous numbers. Some intern did a 5 minute mockup of a ride hailing service which will have a shitload of regulatory hurdles to overcome and is probably.no where near ready to deploy.
Shroomie Dramericanjesus: that's a ceo that I want in my portfolio
Gary Investz : almost fell asleep watching his video
EverDust : Elon Musk is willing to do anything to secure his 56b compensation package, by pumping up stocks with unrealistic expectations, even the executives left one by one. That one stock to stay away from.
MonkeyGee : at the end of the day, the news doesn't matter. The AI will move the stock in the direction with the least positions.